Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development (2021)
Sequence: LLIILRRRIRKQAHAHSK
antisense oligonucleotide (ASO; chimeric)
| Experiment Id | EXP002017 |
|---|---|
| Paper | Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development |
| Peptide | pVEC |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | ASO1–pVEC tested 150–2000 nM; MIC80 700 nM (~5 µg/mL) |
| Rna Concentration | same as peptide (conjugated ASO1–pVEC): 150–2000 nM; MIC80 700 nM |
| Mixing Ratio | |
| Formulation Format | CPP–ASO conjugate (ASO1–pVEC) |
| Formulation Components | ASO1 (16-mer chimeric ASO with PS + 2′-O-alkyl mods) + pVEC |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro (bacterial culture) |
| Cell Lines Or Primary Cells | Staphylococcus aureus ATCC 25923 (also tested specificity in E. coli K12 and Bacillus subtilis 168) |
| Animal Model | |
| Administration Route | |
| Output Type | MIC80 / growth inhibition |
| Output Value | MIC80 = 700 nM (≈5 µg/mL) for S. aureus growth inhibition |
| Output Units | |
| Output Notes | Growth inhibition monitored by OD600 over time; glmS RNA inhibition supported by PCR (absence of amplification with ASO1–pVEC). |
| Toxicity Notes | pVEC alone showed no inhibition of S. aureus growth up to 2000 nM; ASO1 without pVEC ineffective (cannot cross bacterial membrane). |
| Curation Notes |